Human Genome Sciences Inc. filed a plan with regulators Thursday to try to block GlaxoSmithKline P.L.C.’s $2.6 billion takeover offer for the Maryland-based pharmaceutical company.
Human Genome Sciences Inc. filed a plan with regulators Thursday to try to block GlaxoSmithKline P.L.C.’s $2.6 billion takeover offer for the Maryland-based pharmaceutical company.
